Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 14/20 | 0.75 |
| ▸ | HTR2C | P28335 | 12/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.75 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.58 |
| ▸ | TMIGD3 | P0DMS9 | 7/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464939 | 1.00 | HTR2B (0.75) | HTR2BHTR2CADORA3ADRA2BHTR2A | |
| SCHEMBL19807536 | 1.00 | HTR2B (0.75) | HTR2BHTR2CADORA3ADRA2BHTR2A | |
| SCHEMBL19464936 | 1.00 | HTR2B (0.75) | HTR2BHTR2CADORA3ADRA2BHTR2A | |
| SCHEMBL19464923 | 1.00 | HTR2B (0.75) | HTR2BHTR2CADORA3ADRA2BHTR2A | |
| SCHEMBL19464987 | 0.90 | HTR2B (0.63) | HTR2BHTR2CADORA3ADRA2BHTR2A | |
| SCHEMBL19799161 | 0.87 | HTR2B (0.79) | HTR2BHTR2CADORA3ADORA1TMIGD3 | |
| SCHEMBL19459518 | 0.87 | HTR2B (0.79) | HTR2BHTR2CADORA3ADORA1TMIGD3 | |
| SCHEMBL19459477 | 0.87 | HTR2B (0.79) | HTR2BHTR2CADORA3ADORA1TMIGD3 | |
| SCHEMBL19459443 | 0.87 | HTR2B (0.79) | HTR2BHTR2CADORA3ADORA1TMIGD3 | |
| SCHEMBL23098401 | 0.86 | P2RY1 (0.73) | HTR2BHTR2CADORA3ADRA2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | HTR2B 1044/4885HTR2C 1443/4885ADORA3 778/4885 |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | HTR2B 1044/4885HTR2C 1443/4885ADORA3 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.